Millendo Therapeutics, Inc

(NASDAQ:MLND)

Latest On Millendo Therapeutics, Inc (MLND):

Date/Time Type Description Signal Details
2021-03-29 14:16 ESTNewsMillendo stock slumps on merger deal with Tempest TherapeuticsN/A
2021-01-29 03:30 ESTNewsMillendo discloses restructuring plan to cut up to 85% of its workforceN/A
2021-01-07 08:09 ESTAnalyst RatingThe Analyst Target Price has decreased from $3 to $2.Neutral
2021-01-06 16:11 ESTFinancialsCompany financials have been released.Neutral
2021-01-06 08:10 ESTAnalyst RatingThe Analyst Target Price has decreased from $4 to $3.Neutral
2021-01-05 17:52 ESTNewsMillendo Therapeutics shares drop after pulling plug on MLE-301 developmentN/A
2020-11-26 20:49 ESTFinancialsCompany financials have been released.Neutral
2020-11-10 20:41 ESTFinancialsCompany financials have been released.Neutral
2020-11-10 12:34 ESTEarnings EstimateAn EPS average of -$0.45 is estimated for the quarter ending on March 31, 2021.Sell
2020-11-10 12:34 ESTAnalyst RatingThe Analyst Target Price has decreased from $4.33 to $4.Neutral
2020-11-09 13:52 ESTNewsMillendo Therapeutics EPS beats by $0.12N/A
2020-11-07 16:29 ESTFinancialsCompany financials have been released.Neutral
2020-09-26 13:24 ESTFinancialsCompany financials have been released.Neutral
2020-09-24 18:51 ESTNewsMillendo launches early-stage study of lead drugN/A
2020-09-17 05:30 ESTFinancialsCompany financials have been released.Neutral
2020-09-01 21:08 ESTFinancialsCompany financials have been released.Neutral
2020-08-29 21:11 ESTFinancialsCompany financials have been released.Neutral
2020-08-26 05:17 ESTFinancialsCompany financials have been released.Neutral
2020-08-22 17:11 ESTFinancialsCompany financials have been released.Neutral
2020-08-19 09:12 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 09:28 ESTFinancialsCompany financials have been released.Neutral
2020-08-12 13:16 ESTFinancialsCompany financials have been released.Neutral
2020-08-10 17:13 ESTNewsMillendo Therapeutics EPS misses by $0.01N/A
2020-07-31 01:40 ESTFinancialsCompany financials have been released.Neutral
2020-07-23 17:44 ESTFinancialsCompany financials have been released.Neutral
2020-07-09 09:21 ESTFinancialsCompany financials have been released.Neutral
2020-07-07 17:11 ESTAnalyst RatingThe Analyst Target Price has decreased from $4.8 to $4.33.Neutral
2020-07-01 17:08 ESTFinancialsCompany financials have been released.Neutral
2020-06-26 09:20 ESTFinancialsCompany financials have been released.Neutral
2020-06-24 11:20 ESTNewsMillendo under pressure after bailing on nevanimibeN/A
2020-06-16 05:07 ESTAnalyst RatingThe Analyst Target Price has increased from $4.33 to $4.8.Buy
2020-06-15 01:10 ESTAnalyst RatingThe Analyst Target Price has decreased from $4.57 to $4.33.Neutral
2020-06-12 05:25 ESTFinancialsCompany financials have been released.Neutral
2020-06-02 17:21 ESTAnalyst RatingThe Analyst Target Price has increased from $4.5 to $4.57.Buy
2020-06-02 17:21 ESTEarnings EstimateAn EPS average of -$0.51 is estimated for the quarter ending on September 30, 2020.Buy
2020-05-27 05:31 ESTFinancialsCompany financials have been released.Neutral
2020-05-10 01:18 ESTFinancialsCompany financials have been released.Neutral
2020-05-09 12:23 ESTNewsMillendo Therapeutics EPS beats by $0.02N/A
2020-05-06 05:37 ESTFinancialsCompany financials have been released.Neutral
2020-05-01 05:09 ESTFinancialsCompany financials have been released.Neutral
2020-04-12 02:13 ESTNewsMillendo Therapeutics EPS misses by $0.06N/A
2020-04-12 01:43 ESTNewsMillendo Therapeutics' livoletide flunks study; shares crater 69% premarketN/A
2020-04-09 13:04 ESTAnalyst RatingThe Analyst Target Price has decreased from $13.17 to $4.5.Neutral
2020-04-08 01:11 ESTAnalyst RatingThe Analyst Target Price has decreased from $26.67 to $13.17.Neutral
2020-04-06 05:01 ESTAnalyst RatingThe Analyst Target Price has increased from $25.71 to $26.67.Buy
2020-04-03 01:19 ESTFinancialsCompany financials have been released.Neutral
2020-04-02 05:00 ESTFinancialsCompany financials have been released.Neutral
2020-03-31 01:09 ESTAnalyst RatingThe Analyst Target Price has decreased from $26.14 to $25.71.Neutral
2020-03-13 05:05 ESTFinancialsCompany financials have been released.Neutral
2020-03-12 05:03 ESTEarnings EstimateAn EPS average of -$0.67 is estimated for the quarter ending on June 30, 2020.Buy

About Millendo Therapeutics, Inc (MLND):

Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.

MLND Quotes by TradingView

See Advanced Chart

General

  • Name Millendo Therapeutics, Inc
  • Symbol MLND
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 24
  • Last Split Factor1:15
  • Last Split Date2018-12-10
  • Fiscal Year EndDecember
  • IPO Date2012-11-12
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Web URLhttp://www.millendo.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 1.03
  • Enterprise Value EBITDA 0.07
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.46
  • Return on Assets -48%
  • Return on Equity -99%
  • Earnings Per Share -$4.87
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 43.13 million
  • EBITDA -34481000
  • Analyst Target Price $2
  • Book Value Per Share $2.06
View More

Share Statistics

  • Shares Outstanding 19 million
  • Shares Float 16.04 million
  • % Held by Insiders 629%
  • % Held by Institutions 41.79%
  • Shares Short 313021
  • Shares Short Prior Month 436722
  • Short Ratio 0.45
  • Short % of Float 2%
  • Short % of Shares Outstanding 2%
View More

Technicals

  • Beta 0.63
  • 52 Week High $7.02
  • 52 Week Low $1.3
  • 50 Day Moving Average 2.23
  • 200 Day Moving Average 1.87
View More

Dividends

  • Dividend Date 2018-12-10
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Millendo Therapeutics, Inc (MLND) Dividend Calendar:

MLND's last dividend payment was made to shareholders on December 10, 2018.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Millendo Therapeutics, Inc (MLND) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-09$N/A-$0.34-$0.4626.09%
2020-06-302020-08-10$N/A-$0.56-$0.55-2.43%
2020-03-312020-05-08$N/A-$0.65-$0.672.5%
2019-12-312020-03-11$N/A-$0.87-$0.81-7.25%
2019-09-302019-11-13$N/A-$0.87-$0.83-5.33%
2019-06-302019-08-12$N/A-$0.74-$0.818.42%
2019-03-312019-05-15$N/A-$0.78-$0.70-10.91%
2018-12-312019-03-29$N/A-$0.82-$0.864.65%
2018-09-302018-11-09$55000-$2.38
2018-06-302018-08-09$81000-$3.23
2018-03-312018-05-03$67000-$3.09
2017-12-312018-03-15$155000-$3.60-$4.1312.83%
2017-09-302017-11-02$56000-$3.90-$5.9834.78%
2017-06-302017-08-03$84000-$7.65-$6.29-21.62%
2017-03-312017-05-09-$6.30-$6.401.56%
2016-12-312017-03-02$121000-$7.35-$8.6615.13%
2016-09-302016-11-03$197000-$0.54-$0.6111.48%
2016-06-302016-08-04$189000-$0.62-$0.7820.51%
2016-03-312016-05-05$146000-$0.80-$0.72-11.11%
2015-12-312016-02-25$157000-$0.76-$0.70-8.57%
2015-09-302015-11-05$75000-$0.66-$0.671.49%
2015-06-302015-08-10$30000-$0.64-$0.640%
2015-03-312015-05-11$15000-$0.65-$0.707.14%
2014-12-312015-03-16-$0.79-$0.59-33.9%
2014-09-302014-11-10$N/A-$0.54-$0.45-20%
2014-06-302014-08-07$N/A-$6.30-$6.776.94%
2014-03-312014-05-08$N/A-$6.15-$6.9511.51%
2013-12-312014-02-27-$5.40-$5.908.47%
2013-09-302013-11-13$N/A-$6.00-$5.17-16.05%
2013-06-302013-08-13$N/A-$5.40-$4.12-31.07%
2013-03-312013-05-15$N/A-$5.85-$4.12-41.99%
2012-12-312013-02-25-$4.95-$4.35-13.79%
2012-09-302012-11-28$N/A-$6.29

Millendo Therapeutics, Inc (MLND) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Research Development N/A N/A N/A 8.35 million 7.31 million
Income Before Tax N/A N/A N/A -12.7 million -11.63 million
Selling General Administrative N/A N/A N/A 4.48 million 4.44 million
Gross Profit N/A N/A N/A N/A N/A
Ebit N/A N/A N/A -12.83 million -11.75 million
Operating Income N/A N/A N/A -12.83 million -11.75 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A N/A 132000 119000
Net Income From Continuing Operations N/A N/A N/A -12.7 million -11.63 million
Net Income Applicable to Common Shares -6.37 million -10.67 million -12 million -12.7 million -11.63 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A N/A N/A N/A
Change to Liabilities 368000 -1.42 million 1.33 million -1.28 million N/A
Total Cash Flow from Investing Activities N/A N/A -26000 -33000 N/A
Net Borrowings -63000 -8000 -10000 -59000 N/A
Total Cash Flow from Financial Activities N/A N/A N/A 26.86 million N/A
Change to Operating Activities -2.88 million 2.95 million -852000 -280000 N/A
Change in Cash N/A N/A N/A 15.16 million N/A
Total Cash from Operating Activities -7.1 million -7.87 million -10.16 million -11.69 million N/A
Depreciation N/A N/A N/A 1000000 N/A
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities N/A N/A -197000 230000 N/A
Change to Net Income 1.49 million 980000 N/A 1.57 million N/A
Capital Expenditures N/A N/A N/A 33000 N/A
Balance Sheet:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Total Liabailities N/A N/A N/A 15.1 million 13.65 million
Total Stockholder Equity N/A N/A N/A 58.55 million 44.83 million
Other Current Liabilities N/A N/A N/A N/A N/A
Total Assets N/A N/A N/A 74.97 million 58.48 million
Common Stock 19000 19000 19000 18000 44.83 million
Other Current Assets 540000 N/A N/A 1.03 million N/A
Retained Earnings -237.7 million -231.32 million -220.65 million -208.65 million N/A
Other Liabilities N/A N/A 7000 16000 13.65 million
Other Assets 389000 444000 555000 507000 10.13 million
Cash N/A N/A N/A 62.48 million 48.35 million
Total Current Liabilities 7.12 million N/A N/A 12.52 million N/A
Other Stockholder Equity 274000 118000 123000 165000 N/A
Property, Plant & Equipment 2.36 million 2.62 million 2.87 million 3.33 million N/A
Total Current Assets 46.09 million N/A N/A 71.13 million 48.35 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 39.15 million 44.28 million 53.83 million 58.55 million 44.83 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A N/A N/A 168000 N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 1.73 million N/A N/A 1.5 million N/A

Millendo Therapeutics, Inc (MLND) Chart:

Millendo Therapeutics, Inc (MLND) News:

Below you will find a list of latest news for Millendo Therapeutics, Inc (MLND) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Millendo Therapeutics, Inc (MLND) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Millendo Therapeutics, Inc (MLND) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1544227/000110465920075873/0001104659-20-075873-index.htm
2019-04-12UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1544227/000000000019007092/0000000000-19-007092-index.htm
2019-02-01SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1544227/000005341719000055/0000053417-19-000055-index.htm
2018-12-17SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1544227/000093041318003561/0000930413-18-003561-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1544227/000093041319000569/0000930413-19-000569-index.htm
2018-12-20424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1544227/000104746918007756/0001047469-18-007756-index.htm
2019-04-05S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1544227/000104746919002022/0001047469-19-002022-index.htm
2019-04-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1544227/000104746919002693/0001047469-19-002693-index.htm
2019-12-04424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1544227/000104746919006634/0001047469-19-006634-index.htm
2019-12-05424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1544227/000104746919006670/0001047469-19-006670-index.htm
2020-03-04424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1544227/000104746920001193/0001047469-20-001193-index.htm
2018-12-18SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1544227/000107261318000563/0001072613-18-000563-index.htm
2018-12-13SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1544227/000110465918072717/0001104659-18-072717-index.htm
2018-12-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1544227/000110465918072810/0001104659-18-072810-index.htm
2018-12-17SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1544227/000110465918073347/0001104659-18-073347-index.htm
2018-12-17SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1544227/000110465918073351/0001104659-18-073351-index.htm
2018-12-17SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1544227/000110465918073366/0001104659-18-073366-index.htm
2019-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1544227/000110465919001011/0001104659-19-001011-index.htm
2019-01-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1544227/000110465919002767/0001104659-19-002767-index.htm
2019-02-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1544227/000110465919006384/0001104659-19-006384-index.htm
2019-04-05S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1544227/000110465919020207/0001104659-19-020207-index.htm
2019-04-16CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1544227/000110465919021695/0001104659-19-021695-index.htm
2019-04-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1544227/000110465919021957/0001104659-19-021957-index.htm
2019-04-29DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1544227/000110465919024589/0001104659-19-024589-index.htm
2019-06-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1544227/000110465919035378/0001104659-19-035378-index.htm
2019-06-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1544227/000110465919036064/0001104659-19-036064-index.htm
2019-12-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1544227/000110465919070199/0001104659-19-070199-index.htm
2019-12-16S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1544227/000110465919072796/0001104659-19-072796-index.htm
2019-12-16SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1544227/000110465919072949/0001104659-19-072949-index.htm
2019-12-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1544227/000110465919074096/0001104659-19-074096-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1544227/000110465920003161/0001104659-20-003161-index.htm
2020-02-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1544227/000110465920012871/0001104659-20-012871-index.htm
2020-03-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1544227/000110465920028925/0001104659-20-028925-index.htm
2020-04-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1544227/000110465920043387/0001104659-20-043387-index.htm
2020-06-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1544227/000110465920075873/0001104659-20-075873-index.htm
2020-07-30SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1544227/000110465920088216/0001104659-20-088216-index.htm
2019-02-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1544227/000113777419000049/0001137774-19-000049-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1544227/000117266120000845/0001172661-20-000845-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1544227/000119312519039500/0001193125-19-039500-index.htm
2020-04-08SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1544227/000119312520101340/0001193125-20-101340-index.htm
2018-12-113Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919118062092/0001209191-18-062092-index.htm
2018-12-113Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919118062094/0001209191-18-062094-index.htm
2018-12-113Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919118062095/0001209191-18-062095-index.htm
2018-12-113Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919118062096/0001209191-18-062096-index.htm
2018-12-113Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919118062097/0001209191-18-062097-index.htm
2018-12-113Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919118062098/0001209191-18-062098-index.htm
2018-12-113Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919118062100/0001209191-18-062100-index.htm
2018-12-113Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919118062103/0001209191-18-062103-index.htm
2018-12-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919118062104/0001209191-18-062104-index.htm
2018-12-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919118062105/0001209191-18-062105-index.htm
2018-12-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919118062106/0001209191-18-062106-index.htm
2018-12-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919118062107/0001209191-18-062107-index.htm
2018-12-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919118062108/0001209191-18-062108-index.htm
2018-12-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919118062111/0001209191-18-062111-index.htm
2018-12-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919118062113/0001209191-18-062113-index.htm
2018-12-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919118062116/0001209191-18-062116-index.htm
2018-12-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919118062117/0001209191-18-062117-index.htm
2018-12-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919118062119/0001209191-18-062119-index.htm
2018-12-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919118062120/0001209191-18-062120-index.htm
2018-12-113Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919118062123/0001209191-18-062123-index.htm
2018-12-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919118062124/0001209191-18-062124-index.htm
2018-12-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919118062125/0001209191-18-062125-index.htm
2018-12-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919118062126/0001209191-18-062126-index.htm
2018-12-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919118062127/0001209191-18-062127-index.htm
2019-01-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919119004226/0001209191-19-004226-index.htm
2019-01-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919119004228/0001209191-19-004228-index.htm
2019-01-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919119004231/0001209191-19-004231-index.htm
2019-01-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919119004235/0001209191-19-004235-index.htm
2019-01-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919119004237/0001209191-19-004237-index.htm
2019-01-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919119004239/0001209191-19-004239-index.htm
2019-01-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919119004241/0001209191-19-004241-index.htm
2019-01-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919119004242/0001209191-19-004242-index.htm
2019-01-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919119004243/0001209191-19-004243-index.htm
2019-01-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919119004245/0001209191-19-004245-index.htm
2019-01-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919119004246/0001209191-19-004246-index.htm
2019-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919119038475/0001209191-19-038475-index.htm
2019-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919119038478/0001209191-19-038478-index.htm
2019-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919119038479/0001209191-19-038479-index.htm
2019-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919119038481/0001209191-19-038481-index.htm
2019-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919119038482/0001209191-19-038482-index.htm
2019-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919119038485/0001209191-19-038485-index.htm
2019-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919119038486/0001209191-19-038486-index.htm
2019-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919119038488/0001209191-19-038488-index.htm
2019-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919119038489/0001209191-19-038489-index.htm
2019-08-203Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919119046914/0001209191-19-046914-index.htm
2019-08-203Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919119046915/0001209191-19-046915-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919119046917/0001209191-19-046917-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919119046918/0001209191-19-046918-index.htm
2019-12-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919119061354/0001209191-19-061354-index.htm
2019-12-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919119061358/0001209191-19-061358-index.htm
2020-02-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919120006345/0001209191-20-006345-index.htm
2020-02-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919120006355/0001209191-20-006355-index.htm
2020-02-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919120006361/0001209191-20-006361-index.htm
2020-02-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919120006367/0001209191-20-006367-index.htm
2020-02-113Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919120008367/0001209191-20-008367-index.htm
2020-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919120008370/0001209191-20-008370-index.htm
2020-03-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919120021851/0001209191-20-021851-index.htm
2020-05-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919120032485/0001209191-20-032485-index.htm
2020-05-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919120032486/0001209191-20-032486-index.htm
2020-05-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919120032487/0001209191-20-032487-index.htm
2020-05-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919120032488/0001209191-20-032488-index.htm
2020-05-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000120919120032489/0001209191-20-032489-index.htm
2019-02-15SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1544227/000138713119001297/0001387131-19-001297-index.htm
2020-03-17SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1544227/000138713120002923/0001387131-20-002923-index.htm
2020-03-1110-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1544227/000154422720000004/0001544227-20-000004-index.htm
2020-04-24DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1544227/000154422720000008/0001544227-20-000008-index.htm
2020-04-24DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1544227/000154422720000010/0001544227-20-000010-index.htm
2020-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1544227/000154422720000014/0001544227-20-000014-index.htm
2020-06-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000154422720000029/0001544227-20-000029-index.htm
2020-06-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000154422720000030/0001544227-20-000030-index.htm
2020-06-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000154422720000031/0001544227-20-000031-index.htm
2020-06-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000154422720000032/0001544227-20-000032-index.htm
2020-06-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000154422720000033/0001544227-20-000033-index.htm
2020-06-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000154422720000034/0001544227-20-000034-index.htm
2020-06-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1544227/000154422720000035/0001544227-20-000035-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1544227/000154422720000039/0001544227-20-000039-index.htm
2020-09-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1544227/000154422720000042/0001544227-20-000042-index.htm
2019-03-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1544227/000155837019002387/0001558370-19-002387-index.htm
2019-03-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1544227/000155837019002584/0001558370-19-002584-index.htm
2019-04-0110-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1544227/000155837019002660/0001558370-19-002660-index.htm
2019-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1544227/000155837019005038/0001558370-19-005038-index.htm
2019-08-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1544227/000155837019007932/0001558370-19-007932-index.htm
2019-11-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1544227/000155837019010887/0001558370-19-010887-index.htm
2019-02-06SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1544227/000156761919002498/0001567619-19-002498-index.htm
2019-04-18EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1544227/999999999519000760/9999999995-19-000760-index.htm

Millendo Therapeutics, Inc (MLND) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Millendo Therapeutics, Inc (MLND). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 629%
Institutional Ownership: 4179%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-12-07RANDALL W WHITCOMBDirectorBuy15,784.0015,784.00https://www.sec.gov/Archives/edgar/data/1544227/000120919118062127/0001209191-18-062127-index.htm
2018-12-07Carol Giltner GallagherDirectorBuy23,684.0023,684.00https://www.sec.gov/Archives/edgar/data/1544227/000120919118062111/0001209191-18-062111-index.htm
2018-12-07MARY FISHERDirectorBuy355.003,319.00https://www.sec.gov/Archives/edgar/data/1544227/000120919118062108/0001209191-18-062108-index.htm
2018-12-07RICHARD ALDRICHDirectorBuy755.006,169.00https://www.sec.gov/Archives/edgar/data/1544227/000120919118062104/0001209191-18-062104-index.htm
2018-12-07Pharis MohideenChief Medical OfficerBuy7,440.007,440.00https://www.sec.gov/Archives/edgar/data/1544227/000120919118062125/0001209191-18-062125-index.htm
2018-12-07Julia C. OwensPresident and CEOBuy74,400.0074,400.00https://www.sec.gov/Archives/edgar/data/1544227/000120919118062126/0001209191-18-062126-index.htm
2018-12-07MARC D KOZINDirectorBuy831.007,740.00https://www.sec.gov/Archives/edgar/data/1544227/000120919118062119/0001209191-18-062119-index.htm
2018-12-07Carol Giltner GallagherDirectorBuy8,249.008,249.00https://www.sec.gov/Archives/edgar/data/1544227/000120919118062111/0001209191-18-062111-index.htm